{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:19:05Z","timestamp":1760300345490},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologe"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>F\u00fcr Lungenkarzinome mit bestimmten molekulargenetischen Ver\u00e4nderungen des<jats:italic>ALK<\/jats:italic>-,<jats:italic>BRAF<\/jats:italic>- oder<jats:italic>EGFR<\/jats:italic>-Gens gibt es zielgerichtete Therapien, die auch in der Erstlinientherapie zugelassen sind. Oftmals steht f\u00fcr die molekularpathologische Testung nur ein begrenztes Probenmaterial in Form von Biopsien zur Verf\u00fcgung. In einigen F\u00e4llen weisen die Biopsien nach Standardf\u00e4rbungen und immunhistochemischen F\u00e4rbungen keinen oder einen zu geringen Tumoranteil auf, um PCR-basierte Untersuchungen oder FISH(Fluoreszenz-in-situ-Hybridisierung)-Analysen damit durchzuf\u00fchren. In solchen F\u00e4llen kann auf zytologische Pr\u00e4parate wie Bronchusb\u00fcrstenausstriche, transbronchiale Nadelaspiration (TBNA), Bronchiallavage, Punktionsausstriche von Lymphknotenmetastasen oder peripheren Metastasen, Pleuraerguss, Aszites und Perikarderguss zur\u00fcckgegriffen werden. Standardf\u00e4rbungen wie HE, Pappenheim und Papanicolaou sowie immunhistologische Pr\u00e4parate k\u00f6nnen nach der morphologischen Analyse und Diagnosesicherung verwendet werden, um daraus DNA zu extrahieren. Ein Zytopathologe markiert hierf\u00fcr die Tumorzellareale vorher auf dem Objekttr\u00e4ger. Nur bei ausreichend hohem Tumorzellanteil ist es m\u00f6glich, diese Areale zu dissezieren und DNA zu extrahieren. Um eine FISH-Analyse mit den zytologischen Pr\u00e4paraten durchzuf\u00fchren, m\u00fcssen vom Zytopathologen m\u00f6glichst kleine Areale mit mehr als 100\u00a0Tumorzellen eingezeichnet werden. Bereits gef\u00e4rbte Schnitte werden vor der Hybridisierungsreaktion entf\u00e4rbt. Ziel ist es, auch bei begrenztem Ausgangsmaterial eine umfangreiche Diagnostik zu erreichen und Rebiopsien zu vermeiden. In der Pathologie der Uniklinik K\u00f6ln wurden im Zeitraum von 2016 bis Juli\u00a02019 1711\u00a0NGS(Next Generation Sequencing)- und FISH-Analysen an zytologischen Pr\u00e4paraten durchgef\u00fchrt. Dabei lag die Erfolgsrate der NGS-Untersuchungen mit 85,9\u202f% leicht \u00fcber der Erfolgsrate der FISH-Analysen mit 82,8\u202f%.<\/jats:p>","DOI":"10.1007\/s00292-019-00733-3","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T12:02:57Z","timestamp":1578916977000},"page":"39-45","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Molekularpathologische Diagnostik an zytologischen Pr\u00e4paraten"],"prefix":"10.1007","volume":"41","author":[{"given":"Jana","family":"Fassunke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Ball","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Engels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"key":"733_CR1","doi-asserted-by":"publisher","first-page":"13306","DOI":"10.1073\/pnas.0405220101","volume":"101","author":"W Pao","year":"2004","unstructured":"Pao\u00a0W et\u00a0al (2004) EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S\u00a0A 101:13306\u201313311","journal-title":"Proc Natl Acad Sci U S A"},{"key":"733_CR2","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1158\/1078-0432.CCR-13-0657","volume":"19","author":"S Cardarella","year":"2013","unstructured":"Cardarella\u00a0S et al (2013) Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 19:4532\u20134540","journal-title":"Clin Cancer Res"},{"key":"733_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda\u00a0M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561\u2013566","journal-title":"Nature"},{"key":"733_CR4","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.jtho.2017.08.002","volume":"12","author":"JJ Lin","year":"2017","unstructured":"Lin\u00a0JJ, Shaw\u00a0AT (2017) Recent advances in targeting ROS1 in lung cancer. J\u00a0Thorac Oncol 12:1611\u20131625","journal-title":"J Thorac Oncol"},{"key":"733_CR5","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/cncy.21899","volume":"125","author":"P Pisapia","year":"2017","unstructured":"Pisapia\u00a0P et\u00a0al (2017) ALK and ROS1 testing on lung cancer cytologic samples: perspectives. Cancer Cytopathol 125:817\u2013830","journal-title":"Cancer Cytopathol"},{"key":"733_CR6","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1158\/1078-0432.CCR-14-0450","volume":"21","author":"HU Schildhaus","year":"2015","unstructured":"Schildhaus\u00a0HU et al (2015) MET amplification status in therapy-naive adeno- and squamous cell carcinomas of the lung. Clin Cancer Res 21:907\u2013915","journal-title":"Clin Cancer Res"},{"key":"733_CR7","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jtho.2015.10.025","volume":"11","author":"BT Li","year":"2016","unstructured":"Li\u00a0BT et\u00a0al (2016) HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers. J\u00a0Thorac Oncol 11:414\u2013419","journal-title":"J Thorac Oncol"},{"key":"733_CR8","volume-title":"Classification of tumours of the lung, pleura, thymus and heart","author":"AG Nicholson","year":"2015","unstructured":"Nicholson\u00a0AG, Geisinger\u00a0K, Aisner\u00a0SC et al (2015) Tumours of the lung- terminology and criteria in non-resection specimens. In: WHO (Hrsg) Classification of tumours of the lung, pleura, thymus and heart, 4.\u00a0Aufl.","edition":"4"},{"key":"733_CR9","volume-title":"Molecular pathology with online resource: a practical guide for the surgical pathologist and cytopathologist","author":"JMS Bartlett","year":"2016","unstructured":"Bartlett\u00a0JMS, Shaaban\u00a0A, Schmitt\u00a0F (2016) Molecular pathology with online resource: a practical guide for the surgical pathologist and cytopathologist"},{"key":"733_CR10","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/cncy.21844","volume":"125","author":"JE Baum","year":"2017","unstructured":"Baum\u00a0JE et al (2017) Accuracy of next-generation sequencing for the identification of clinically relevant variants in cytology smears in lung adenocarcinoma. Cancer Cytopathol 125:398\u2013406","journal-title":"Cancer Cytopathol"},{"key":"733_CR11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1159\/000479217","volume":"61","author":"D Jain","year":"2017","unstructured":"Jain\u00a0D et al (2017) Use of exfoliative specimens and fine-needle aspiration smears for mutation testing in lung adenocarcinoma. Acta Cytol 61:455\u2013461","journal-title":"Acta Cytol"},{"key":"733_CR12","volume-title":"Lung and mediastinum cytohistology","author":"GCH Yang","year":"2012","unstructured":"Yang\u00a0GCH, Ali\u00a0SZ (2012) Lung and mediastinum cytohistology"},{"key":"733_CR13","doi-asserted-by":"crossref","DOI":"10.1159\/isbn.978-3-318-02397-8","volume-title":"Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA): a practical approach","author":"SE von Monaco","year":"2014","unstructured":"von Monaco\u00a0SE, Khalbuss\u00a0WE, Pantanowitz\u00a0L (2014) Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA): a practical approach"},{"key":"733_CR14","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/cncy.20181","volume":"120","author":"GR Collins","year":"2012","unstructured":"Collins\u00a0GR, Thomas\u00a0J, Joshi\u00a0N, Zhang\u00a0S (2012) The diagnostic value of cell block as an adjunct to liquid-based cytology of bronchial washing specimens in the diagnosis and subclassification of pulmonary neoplasms. Cancer Cytopathol 120:134\u2013141","journal-title":"Cancer Cytopathol"},{"key":"733_CR15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1055\/s-0032-1326344","volume":"67","author":"FJ Herth","year":"2013","unstructured":"Herth\u00a0FJ et al (2013) Diagnostic and predictive analyses of cytological specimens of non-small cell lung cancer: strategies and challenges. Pneumologie 67:198\u2013204","journal-title":"Pneumologie"},{"key":"733_CR16","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/cncy.21306","volume":"121","author":"G da Cunha Santos","year":"2013","unstructured":"da Cunha Santos\u00a0G et\u00a0al (2013) Minimizing delays in DNA retrieval: the \u201cfreezer method\u201d for glass coverslip removal. Letter to the editor regarding comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas. Cancer Cytopathol 121:533","journal-title":"Cancer Cytopathol"},{"key":"733_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00408-019-00213-8","volume":"197","author":"L Hagmeyer","year":"2019","unstructured":"Hagmeyer\u00a0L et al (2019) Bronchoscopic brushing from central lung cancer-next generation sequencing results are reliable. Lung 197:333\u2013337","journal-title":"Lung"},{"key":"733_CR18","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1159\/000339792","volume":"56","author":"S Savic","year":"2012","unstructured":"Savic\u00a0S, Bubendorf\u00a0L (2012) Role of fluorescence in situ hybridization in lung cancer cytology. Acta Cytol 56:611\u2013621","journal-title":"Acta Cytol"}],"container-title":["Der Pathologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-019-00733-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00292-019-00733-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-019-00733-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:32:03Z","timestamp":1665448323000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00292-019-00733-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["733"],"URL":"https:\/\/doi.org\/10.1007\/s00292-019-00733-3","relation":{},"ISSN":["0172-8113","1432-1963"],"issn-type":[{"value":"0172-8113","type":"print"},{"value":"1432-1963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]},"assertion":[{"value":"13 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Fassunke, M.\u00a0Ball und M.\u00a0Engels geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle beschriebenen Untersuchungen am Menschen oder an menschlichem Gewebe wurden mit Zustimmung der zust\u00e4ndigen Ethikkommission, im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt. Von allen beteiligten Patienten liegt eine Einverst\u00e4ndniserkl\u00e4rung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}